Average Co-Inventor Count = 8.45
ph-index = 8
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Signal Pharmaceuticals, Inc. (11 from 169 patents)
2. Celgene Corporation (3 from 549 patents)
3. Array Biopharma Inc. (3 from 329 patents)
15 patents:
1. 12129237 - Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
2. 11028093 - 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors
3. 10730880 - 4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors
4. 10428145 - PD-1 binding proteins and methods of use thereof
5. 10266500 - Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
6. 10189845 - 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors
7. 9783505 - Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
8. 9701643 - Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
9. 9556126 - Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
10. 9139534 - Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
11. 8680076 - Methods of treatment, improvement and prevention using haloaryl substituted aminopurines
12. 8440661 - Methods of modulating inflammatory cell recruitment and gene expression using haloaryl substituted aminopurines
13. 7759342 - Methods of treatment and prevention using haloaryl substituted aminopurines
14. 7335676 - Methods for treating inflammatory conditions or inhibiting JNK
15. 7119114 - Pyrazoloanthrone and derivatives thereof as JNK inhibitors and compositions and methods related thereto